IL6 and congenital rubella syndrome: Several authors have suggested that CAR T cell-induced CRS is mediated by IL-6, IL-1, and nitric oxide produced by recipient macrophages, and can be attenuated by nitric oxide inhibitors, IL-6 antagonists such as tocilizumab, and IL-1 blockade by Anakinra (37, 38).